| Assessment Status | Rapid review complete |
| HTA ID | 22068 |
| Drug | Empagliflozin |
| Brand | Jardiance® |
| Indication | For the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% |
| Assessment Process | |
| Rapid review commissioned | 02/11/2022 |
| Rapid review completed | 02/12/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that empagliflozin for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% be considered for reimbursement* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
